MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.72
+0.97
+11.09%
Opening 14:57 08/10 EDT
OPEN
9.34
PREV CLOSE
8.75
HIGH
10.15
LOW
9.20
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
10.15
52 WEEK LOW
3.262
MARKET CAP
342.82M
P/E (TTM)
-6.2109
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RDHL stock price target is 20.40 with a high estimate of 27.00 and a low estimate of 16.00.

EPS

RDHL News

More
RedHill Biopharma to Host Second Quarter Financial Results and Business Highlights Conference Call and Webcast on August 13, 2020
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its second quarter 2020 financial results and b
GlobeNewswire · 3d ago
RedHill to launch COVID-19 study in Mexico
The Mexican Federal Committee has signed off on a Phase 2/3 clinical trial evaluating RedHill Biopharma's (NASDAQ:RDHL) Yeliva (opaganib) in severely ill h
seekingalpha · 4d ago
RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico
The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe COVID-19 across 40 clinical sites \-- The global Phase 2/3 study has been approved in Mexico, the UK and Russia and is also under review in Italy, Brazil and additional
GlobeNewswire · 4d ago
RedHill Biopharma to Participate in Upcoming BTIG and Intellisight Conferences
TEL-AVIV, Israel and RALEIGH, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will participate in the following virtual conferences in Au
GlobeNewswire · 5d ago
RedHill Bio inks new agreement with Daiichi Sankyo for Movantik
Seeking Alpha - Article · 08/03 12:55
RedHill and Daiichi Sankyo Replace Their Co-Commercialization Agreement for Movantik Under which RedHill Will Maintain Sole and Exclusive responsibility for the Commercialization of Movantik in the U.S.
Benzinga · 08/03 11:26
RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
RedHill acquired Movantik® for opioid induced constipation from AstraZeneca in April 2020; Movantik® generated $96 million in 2019 \-- RedHill and Daiichi Sankyo replaced their co-commercialization agreement for Movantik® with a new royalty-bearing agreement,
GlobeNewswire · 08/03 11:00
AstraZeneca Nirsevimab Data, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha · 07/31 17:07

Industry

Biotechnology & Medical Research
+0.08%
Pharmaceuticals & Medical Research
+0.02%

Hot Stocks

Symbol
Price
%Change

About RDHL

RedHill Biopharma Ltd. is an Israel-based specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases. The Company promotes the gastrointestinal drug Aemcolo in the United States (U.S.). Its key clinical late-stage development programs include: RHB-104, with positive results from a first Phase 3 study for Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; RHB-102 (Bekinda), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; ABC294640 (Yeliva), RHB-106, and RHB-107.
More

Webull offers kinds of RedHill Biopharma Ltd (ADR) stock information, including NASDAQ:RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.